Danaher (DHR) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Core Insights - Danaher (DHR) reported revenue of $5.94 billion for the quarter ended June 2025, marking a year-over-year increase of 3.4% and an EPS of $1.80 compared to $1.72 a year ago [1] - The reported revenue exceeded the Zacks Consensus Estimate of $5.84 billion, resulting in a surprise of +1.71%, while the EPS surprise was +9.76% against a consensus estimate of $1.64 [1] Financial Performance Metrics - Organic sales growth was 1.5%, aligning with the three-analyst average estimate of 1.5% [4] - Total sales in Diagnostics reached $2.31 billion, surpassing the $2.28 billion estimate, reflecting a +2.2% change year-over-year [4] - Life Sciences total sales were $1.78 billion, exceeding the $1.71 billion estimate, with a +0.4% year-over-year change [4] - Biotechnology total sales amounted to $1.85 billion, above the $1.83 billion estimate, showing an +8% change compared to the previous year [4] - Operating profit for Life Sciences was reported at -$239 million, falling short of the $206.51 million estimate [4] - Operating profit for Biotechnology was $531 million, exceeding the $463.69 million estimate [4] - Operating profit for Diagnostics was $554 million, surpassing the $501.31 million estimate [4] - The stock has returned -4.2% over the past month, contrasting with the Zacks S&P 500 composite's +5.9% change, and currently holds a Zacks Rank 4 (Sell) [3]